Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions

Entropy Neurodynamics (ASX: ENP) has been granted an Australian patent covering lead asset TRP8803 developed as a precision-controlled method of administering psilocybin, psilocin and related candidates to treat a range of psychological and nociplastic pain disorders.

“Nociplastic” refers to a type of chronic pain resulting from heightened signaling in the central nervous system, rather than direct tissue damage or nerve injury.

The patent protects the core intellectual property (IP) underpinning TRP-8803 (intravenous-infused psilocin) through to 2042 and covers the use of Entropy’s proprietary two-phase IV dosing regimen, time to onset of desired treatment state, control of treatment duration, and electroencephalogram (EEG) monitoring for real-time biomarker development.

It also unlocks broad protection across psilocybin, psilocin and related chemical variants for a range of high-value neuropsychiatric indications including fibromyalgia, anxiety, chronic pain, addictions, eating disorders and post-traumatic stress disorder (PTSD).

Multiple Delivery Routes

Entropy expects the multiple maintenance delivery routes – including IV, oral, transdermal, subcutaneous, and intranasal—the patent applies across to help future-proof the company’s asset base as new delivery technologies emerge.

Collectively, the patent secures a defensible, scalable and indication-agnostic treatment platform, providing Entropy with long-life protection around how psychedelic therapies are delivered, monitored, and controlled.

Importantly, it protects Entropy’s ability to rapidly stop treatment by ending the infusion that has significant safety, operational, and commercial advantages not achievable with oral dosing.

The company’s additional patent applications across regions including the US are well advanced.

Enhancing Long-Term Value

Chief executive officer Jason Carroll said the new patent would significantly strengthen Entropy’s IP position and materially enhance the long-term value of TRP-8803.

“We have secured protection around the molecule and the method of delivery — or how the treatment is induced, controlled, monitored and stopped — that creates an extensive barrier to entry that is extremely difficult for competitors to design around,” he said.

“Our two-phase IV model with rapid onset, controlled maintenance and the ability to stop treatment on demand delivers a differentiated clinical profile that is impossible to replicate with oral dosing and being able to secure protection through to 2042 provides long-dated exclusivity over this precision-controlled approach.”

He said the breadth of coverage across compounds, dosing ranges, delivery routes and multiple high-value indications would keep Entropy well-positioned to advance TRP-8803 through clinical development and engage with potential partners focused on next-generation neuropsychiatric therapeutics.